---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-010945"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:01:27.720239+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immunome to acquire AL102 Phase 3 desmoid tumor asset from Ayala for $20M cash + $30M stock

## Summary
- Immunome will acquire AL102 and AL101 from Ayala for $20M cash and ~$30M in stock (2.18M shares).
- Up to $37.5M in development and commercial milestone payments; closing requires Ayala stockholder approval.
- AL102 is a gamma secretase inhibitor in a Phase 3 trial for desmoid tumors; Phase 2 data showed 75% ORR.
- AL102 granted FDA Orphan Drug Designation in Nov 2023; desmoid tumors affect ~1,650 diagnosed annually in U.S.
- Transaction to complement Immunome's targeted cancer pipeline; Ayala's stock trades OTCQX under ADXS.

## SEC filing metadata
- accession: 0001104659-24-010945
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465924010945/0001104659-24-010945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465924010945/tm245249d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-010945
- JSON: https://secwatch.observer/filing/0001104659-24-010945.json
- Plain text: https://secwatch.observer/filing/0001104659-24-010945.txt

## Key facts
- Material Agreements
  Immunome Inc. entered into Asset Purchase Agreement with Ayala Pharmaceuticals, Inc. valued at $20,000,000 (effective 2024-02-05).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Ayala Pharmaceuticals, Inc.
  - Value: $20,000,000
  - Effective: 2024-02-05
  source text: On February 5, 2024, Immunome, Inc. (the “Company”) and Ayala Pharmaceuticals, Inc. (“Ayala”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company will acquire Ayala’s AL101 and AL102 programs and assume certain of Ayala’s liabilities associated with the acquired assets
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465924010945/0001104659-24-010945-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.